close

Enter

Log in using OpenID

Epigenetics Drugs and Diagnostic Technologies Market

embed
The global Epigenetics Drugs And Diagnostic Technologies Market size is expected to reach USD 22.05 billion by 2025
Epigenetics Drugs and Diagnostic Technologies Market Size, Share &
Trends Analysis Report and Segment Forecast, 2025 | Grand View
Research, Inc
“The global epigenetics drugs and diagnostic technologies market size was
valued at USD 5.24 billion in 2017 and is projected to expand at a CAGR of
19.7% over the forecast period. ”
The global Epigenetics Drugs And Diagnostic Technologies Market size is expected to reach USD 22.05
billion by 2025, according to a new report by Grand View Research, Inc. It is projected to expand at a 19.7%
CAGR during the forecast period. Rising incidence of cancer with epigenetic modification base is projected to
drive the market growth.
Diagnostic firms are focused on developing new treatments such as antibodies specific for detection of epigenetic
modifications and advanced kits for effective detection of biomarkers. It is likely to encourage pharmaceutical
firms to partner for development of new advanced treatments which will further accelerate the market growth.
Presence of a large number of products under clinical trials and their projected commercialization is likely to
boost the market. For instance, Eli Lilly’s Ramucirumab have been approved by the U.S. Food and Drug
Administration (FDA) to be used in combination with Folfiri for the treatment of metastatic colorectal cancer.
Introduction of technologically advanced products in this space is mostly focused on detection of methylation
markers associated with cancer development. For example, Epigenomics introduced Epi proLung BL Reflex
Assay which helps in lung cancer diagnosis by determining methylation of SHOX2 biomarker gene.
Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/epigenetics-drugs-anddiagnostic-technologies-market
Follow Us:
Further key findings from the report suggest:

Reagents is expected to account for the largest market share of over USD 7,058.4 million by 2025 owing
to increasing R&D in epigenetics. The kits segment is expected to be in more demand over the forecast
period with at CAGR of 20.0% due to need for rapid and accurate detection techniques

DNA methylation held the major market share of the technology segment in terms of revenue over 47.1%
in 2017 owing to rising adoption coupled with development of technological advanced products such as
Methylation Sensitive PCR (MSP)

DNMT inhibitors was the largest segment in 2017 due to the factors such as wide availability of these
inhibitors and generics in most regions

Oncology was the largest revenue generating segment owing to the factors such as growing prevalence of
cancer and strong product pipeline

North America was observed to be the major region for epigenetics market accounting for over 39.3%
market share due to high prevalence of cancer, increasing R&D funding, collaborations among big
pharmaceutical companies for development of improved treatments, and patient awareness

Asia Pacific is projected to showcase lucrative CAGR of 22.1% owing to a high number of cancer,
diabetes, and other chronic disorders with parallel unmet medical needs

Major players operating in the epigenetics drugs and diagnostic technologies market include Zymo
research; CellCentric Ltd; Thermo Fisher Scientific;Illumina; Abcam; Eisai Co. Ltd; Diagenode; Merck;
Syndax Pharmaceuticals, Inc.; Qiagen; Chroma Therapeutics Ltd; Novartis International AG; Oncolys
Biopharma Inc.; Sigma-Aldrich Corporation; and Valirx Plc. Widespread R&D activities and clinical
studies are expected to boost the market growth over the forecast period.
Grand View Research has segmented the global epigenetics drugs and diagnostic technologies market on the
basis of product, technology, type of therapy, application, and region:
Epigenetics Drugs and Diagnostic Technology Product Outlook (Revenue, USD Million, 2014 - 2025)

Reagents

Kits
Follow Us:
o
ChIP Sequencing Kit
o
Whole Genomic Amplification Kit
o
Bisulfite Conversion Kit
o
RNA Sequencing Kit
o
Others

Instruments

Enzymes

Services
Epigenetics Drugs and Diagnostic Technology Outlook (Revenue, USD Million, 2014 - 2025)

DNA Methylation

Histone Methylation

Histone Acetylation

Large Non-coding RNA

MicroRNA Modification

Chromatin Structures
Epigenetics Drugs and Diagnostic Technologies Type of Therapy Outlook (Revenue, USD Million, 2014 2025)

Histone Deacetylase (HDAC) Inhibitors

DNA Methyltransferase (DNMT) Inhibitors
Epigenetics Drugs and Diagnostic Technologies Application Outlook (Revenue, USD Million, 2014 - 2025)


Oncology
o
Solid Tumors
o
Liquid Tumors
Non-oncology
o
Inflammatory Diseases
o
Metabolic Diseases
o
Infectious Diseases
o
Cardiovascular Diseases
o
Others
Epigenetics Drugs and Diagnostic Technologies Regional Outlook (Revenue, USD Million, 2014 - 2025)

North America
Follow Us:




o
U.S.
o
Canada
Europe
o
U.K.
o
Germany
Asia Pacific
o
Japan
o
China
o
India
Latin America
o
Brazil
o
Mexico
MEA
o
Follow Us:
South Africa
Table of Content of Epigenetics Drugs and Diagnostic Technologies Market
Chapter 1 Research Methodology
1.1 Information procurement
1.2 Information or data analysis
1.3 Market formulation & validation
Chapter 2 Executive Summary
2.1 Market snapshot
Chapter 3 Market Variables, Trends & Scope
3.1 Market segmentation & scope
3.2 Market driver analysis
3.2.1. Increasing prevalence of target diseases
3.2.2 Growing global geriatric population
3.2.3 Increasing collaborations between biotechnology companies, pharmaceutical companies, and
academic research institutes
3.2.4 Presence of funding programs to promote and support research & development
3.2.5 Technological advancements
3.3 Market restraint analysis
3.3.1 Inefficiency in identification and validation of biomarkers
3.3.2 Presence of complex regulatory framework
3.4 Penetration & growth prospect mapping
3.5 Epigenetics drugs and diagnostics technologies market - SWOT analysis, by factor (political & legal,
economic and technological)
3.6 Industry analysis - Porter’s
3.7 Epigenetics drugs and diagnostics technologies market -Pipeline overview
Chapter 4 Epigenetics Drugs and Diagnostics Technologies Market: Product Estimates & Trend Analysis
4.1 Epigenetics drugs and diagnostics technologies market: Product movement analysis
4.2 Reagents
4.2.1 Reagents market estimates and forecasts, 2014 - 2025 (USD Million)
4.3 Kits
4.3.1 Kits market estimates and forecasts, 2014 - 2025 (USD Million)
4.3.2 ChIP sequencing kit
4.3.2.1 ChIP sequencing kit market estimates and forecasts, 2014 - 2025 (USD Million)
4.3.3 Whole-genomic amplification kit
4.3.3.1 Whole-genomic amplification kit market estimates and forecasts, 2014 - 2025 (USD Million)
4.3.4 Bisulfite conversion kit
4.3.4.1 Bisulfite conversion kit market estimates and forecasts, 2014 - 2025 (USD Million)
4.3.5 RNA sequencing kit
4.3.5.1 RNA sequencing Kit market estimates and forecasts, 2014 - 2025 (USD Million)
4.3.6 Others
Follow Us:
4.3.6.1 Others market estimates and forecasts, 2014 - 2025 (USD Million)
4.4 Instruments
4.4.1 Instruments market estimates and forecasts, 2014 - 2025 (USD Million)
4.5 Enzymes
4.5.1 Enzymes market estimates and forecasts, 2014 - 2025 (USD Million)
4.6 Services
4.6.1 Services market estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 5 Epigenetics Drugs and Diagnostics Technologies Market: Technology Estimates & Trend Analysis
5.1 Epigenetics drugs and diagnostics technologies market: Technology movement analysis
5.2 DNA methylation
5.2.1 DNA methylation market estimates and forecasts, 2014 - 2025 (USD Million)
5.3 Histone methylation
5.3.1 Histone methylation market estimates and forecasts, 2014 - 2025 (USD Million)
5.4 Histone acetylation
5.4.1 Histone acetylation market estimates and forecasts, 2014 - 2025 (USD Million)
5.5 Large non-coding RNA
5.5.1 Large non-coding RNA market estimates and forecasts, 2014 - 2025 (USD Million)
5.6 MicroRNA modification
5.6.1 MicroRNA modification market estimates and forecasts, 2014 - 2025 (USD Million)
5.7 Chromatin structures
5.7.1 Chromatin structures market estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 6 Epigenetics Drugs and Diagnostics Technologies Market: Types of Therapies Estimates & Trend
Analysis
6.1 Epigenetics drugs and diagnostics technologies market: Types of therapies movement analysis
6.2 Histone deacetylase (HDAC) inhibitors
6.2.1 HDAC inhibitors market estimates and forecasts, 2014 - 2025 (USD Million)
6.3 DNA methyltransferase (DNMT) inhibitors
6.3.1 DNMT inhibitors market estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 7 Epigenetics Drugs and Diagnostics Technologies Market: Application Estimates & Trend Analysis
7.1 Epigenetics drugs and diagnostics technologies market: Application movement analysis
7.2 Oncology
7.2.1 Oncology market estimates and forecasts, 2014 - 2025 (USD Million)
7.2.2 Solid tumors
7.2.2.1 Solid tumors market estimates and forecasts, 2014 - 2025 (USD Million)
7.2.3 Liquid tumors
7.2.3.1 Liquid tumors market estimates and forecasts, 2014 - 2025 (USD Million)
7.3 Non-oncology disorders
7.3.1 Non-oncology disorders market estimates and forecasts, 2014 - 2025 (USD Million)
7.3.2 Inflammatory diseases
7.3.2.1 Inflammatory diseases market estimates and forecasts, 2014 - 2025 (USD Million)
Follow Us:
7.3.3 Metabolic diseases
7.3.3.1 Metabolic diseases market estimates and forecasts, 2014 - 2025 (USD Million)
7.3.4 Infectious diseases
7.3.4.1 Infectious diseases market estimates and forecasts, 2014 - 2025 (USD Million)
7.3.5 Cardiovascular diseases
7.3.5.1 Cardiovascular diseases market estimates and forecasts, 2014 - 2025 (USD Million)
7.3.6 Others
7.3.6.1 Others market estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 8 Epigenetics Drugs and Diagnostics Technologies Market: Regional Estimates & Trend Analysis
8.1 Epigenetics drugs and diagnostics technologies market share by region, 2017 & 2025
8.2 North America
8.2.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
8.2.2 U.S.
8.2.2.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
8.2.3 Canada
8.2.3.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
8.3 Europe
8.3.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
8.3.2 Germany
8.3.2.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
8.3.3 U.K.
8.3.3.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
8.4 Asia Pacific
8.4.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
8.4.2 Japan
8.4.2.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
8.4.3 China
8.4.3.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
8.4.4 India
8.4.4.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
8.5 Latin America
8.5.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
8.5.2 Brazil
8.5.2.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
8.5.3 Mexico
8.5.3.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
8.6 MEA
8.6.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
8.6.2 South Africa
8.6.2.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
Follow Us:
Chapter 9 Competitive Landscape
9.1 Strategy Framework
9.2 Illumina, Inc.
9.2.1 Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.3 Merck Sharp & Dohme Corp
9.3.1 Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.4 Qiagen
9.4.1 Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.5 F. Hoffmann-La Roche Ltd.
9.5.1 Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.6 Eisai Co., Ltd.
9.6.1 Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.7 Novartis AG
9.7.1 Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.8 Abcam plc
9.8.1 Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.9 Diagenode Diagnostics
9.9.1 Company overview
9.9.2 Financial performance
Follow Us:
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.10 Thermo Fisher Scientific, Inc.
9.10.1 Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.11 Active Motif
9.11.1 Company overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.12 Zymo Research Corporation
9.12.1 Company overview
9.12.2 Financial performance
9.12.3 Product benchmarking
9.12.4 Strategic initiatives
9.13 CellCentric
9.13.1 Company overview
9.13.2 Product benchmarking
9.13.3 Strategic initiatives
9.14 Chroma Therapeutics Ltd.
9.14.1 Company overview
9.14.2 Financial performance
9.14.3 Product benchmarking
9.14.4 Strategic initiatives
9.15 Oncolys BioPharma Inc.
9.15.1 Company overview
9.15.2 Financial performance
9.15.3 Product benchmarking
9.15.4 Strategic initiatives
9.16 Syndax
9.16.1 Company overview
9.16.2 Financial performance
9.16.3 Product benchmarking
9.16.4 Strategic initiatives
9.17 Valirx
9.17.1 Company overview
9.17.2 Financial performance
9.17.3 Product benchmarking
Follow Us:
9.17.4 Strategic initiatives
9.18 Sigma-Aldrich Corporation (Merck KGaA)
9.18.1 Company overview
9.18.2 Financial performance
9.18.3 Product benchmarking
9.18.4 Strategic initiatives
Follow Us:
About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed business decisions, the company offers
market intelligence studies ensuring relevant and fact-based research across a range of industries including
technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: [email protected]
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/
Follow Us:
Author
sara01.james
sara01.james506   documents Email
1/--pages
Report inappropriate content